Suggested remit: To appraise the clinical and cost effectiveness of tofacitinib within its marketing authorisation for treating active ankylosing spondylitis
Status In progress
Process STA 2018
ID number 3865

Provisional Schedule

Committee meeting: 1 09 June 2022
Expected publication 17 August 2022

Project Team

Project lead Thomas Feist

Email enquiries


Key events during the development of the guidance:

Date Update
01 October 2021 We recently contacted all stakeholders for the appraisal of tofacitinib for treating active ankylosing spondylitis regarding a delay to this topic for operational reasons. Tofacitinib for treating active ankylosing spondylitis has now been rescheduled into the work programme. The appraisal is due to start late September 2021 and will be discussed at committee in early June 2022. This appraisal will now follow the Single Technology Appraisal Process and will not be included in a Multiple Technology Appraisal with Upadacitinib for treating active ankylosing spondylitis [ID3848] as originally advised. The new timelines are subject to the work programme capacity and we will continue to review our plans in collaboration with the company and update our stakeholders accordingly.
01 October 2021 In progress. rescheduled back into the work programme
01 October 2021 Invitation to participate
17 June 2021 Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.
25 January 2021 - 22 February 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance